title: Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat.
abstract: Traumatic brain injuries (TBIs) induce profound breakdown of the blood-brain and blood-cerebrospinal fluid barriers (BCSFB), brain pathology/edema, and sensory-motor disturbances. Because neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1), and glial cell-derived neurotrophic factor (GDNF), are neuroprotective in models of brain and spinal cord injuries, we hypothesized that a combination of neurotrophic factors would enhance neuroprotective efficacy. In the present investigation, we examined the effects of Cerebrolysin, a mixture of different neurotrophic factors (Ebewe Neuro Pharma, Austria) on the brain pathology and functional outcome in a rat model of TBI. TBI was produced under Equithesin (3 mL/kg, i.p.) anesthesia by making a longitudinal incision into the right parietal cerebral cortex. Untreated injured rats developed profound disruption of the blood-brain barrier (BBB) to proteins, edema/cell injury, and marked sensory-motor dysfunctions on rota-rod and grid-walking tests at 5 h TBI. Intracerebroventricular administration of Cerebrolysin (10 or 30 microL) either 5 min or 1 h after TBI significantly reduced leakage of Evans blue and radioiodine tracers across the BBB and BCSFB, and attenuated brain edema formation/neuronal damage in the cortex as well as underlying subcortical regions. Cerebrolysin-treated animals also had improved sensory-motor functions. However, administration of Cerebrolysin 2 h after TBI did not affect these parameters significantly. These observations in TBI demonstrate that early intervention with Cerebrolysin reduces BBB and BCSFB permeability changes, attenuates brain pathology and brain edema, and mitigates functional deficits. Taken together, our observations suggest that Cerebrolysin has potential therapeutic value in TBI.
authors.affiliation: Laboratory of Cerebrovascular Research, Institute of Surgical Sciences, Department of Anaesthesiology & Intensive Care, University Hospital, Uppsala University, Uppsala, Sweden. Sharma@surgsci.uu.se
authors.forename: Hari Shanker
authors.initials: HS
authors.lastname: Sharma
authors.forename: Sibilla
authors.initials: S
authors.lastname: Zimmermann-Meinzingen
authors.forename: Conrad E
authors.initials: CE
authors.lastname: Johanson
mesh_terms: D000596:Amino Acids / Q000494:pharmacology*; D000818:Animals; D001930:Brain Injuries / Q000097:blood / Q000134:cerebrospinal fluid / Q000473:pathology* / Q000503:physiopathology; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010539:Permeability; D051381:Rats; D017208:Rats, Wistar; D045442:Rotarod Performance Test
chemical_list: D000596:Amino Acids; D018696:Neuroprotective Agents; C006952:cerebrolysin